Valsartan 'shows promise' in hypertrophic cardiomyopathy

A phase 2 trial suggests early treatment may attenuate cardiac remodelling.

AusDoc brings you the latest news from the European Society of Cardiology Congress 2021.

Box of valsartan showing its molecular structure

Use of valsartan in patients with early hypertrophic cardiomyopathy (HCM) due to a pathogenic sarcomeric gene variant attenuates markers of cardiac remodelling, a trial shows.

The results of the phase 2 Valsartan for Attenuating Disease Evolution in Early-stage Sarcomeric Hypertrophic Cardiomyopathy (VANISH) trial suggest an opportunity